Clinical Trial Update: Non-inferiority of GSK Biologicals' DTPw-HBV/Hib Compared to Two Formulations of GSK Biologicals' DTPw-HBV/Hib [Phase 3]

View source ↗

Summary

Phase 3 trial shows non-inferiority of GSK's DTPw-HBV/Hib vaccine compared to two alternative formulations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Haemophilus Influenzae Type Infection
• Hepatitis B
• Pertussis
• Tetanus

Drugs mentioned

• DTPw-HBV/Hib vaccine (formulation A)
• DTPw-HBV/Hib vaccine (formulation B)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Whole Cell Pertussis, Haemophilus Influenzae Type b | Phase 3 | Status: COMPLETED | Results posted: 2017-08-18